Challenges and future perspectives of T cell immunotherapy in cancer

Immunol Lett. 2015 Aug;166(2):117-33. doi: 10.1016/j.imlet.2015.05.018. Epub 2015 Jun 19.

Abstract

Since the formulation of the tumour immunosurveillance theory, considerable focus has been on enhancing the effectiveness of host antitumour immunity, particularly with respect to T cells. A cancer evades or alters the host immune response by various ways to ensure its development and survival. These include modifications of the immune cell metabolism and T cell signalling. An inhibitory cytokine milieu in the tumour microenvironment also leads to immune suppression and tumour progression within a host. This review traces the development in the field and attempts to summarize the hurdles that the approach of adoptive T cell immunotherapy against cancer faces, and discusses the conditions that must be improved to allow effective eradication of cancer.

Keywords: Cancer immunotherapy; Checkpoint inhibition; Immune activation; Immunoediting; Immunosuppression; T lymphocyte; Tumour escape.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • Bystander Effect / immunology
  • Cell Communication / immunology
  • Cell Transformation, Neoplastic / immunology
  • Cell Transformation, Neoplastic / metabolism
  • Cell- and Tissue-Based Therapy
  • Genetic Engineering
  • Genetic Therapy
  • Humans
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use
  • Immunomodulation
  • Immunotherapy* / methods
  • Neoplasms / immunology*
  • Neoplasms / metabolism
  • Neoplasms / therapy*
  • Signal Transduction
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocytes, Regulatory / immunology
  • Tumor Escape / immunology
  • Tumor Microenvironment / immunology

Substances

  • Antigens, Neoplasm
  • Immunologic Factors